Transcranial Pulse Stimulation (TPS) uses shockwaves for the treatment of Alzheimer´s patients. Recently, our group published short-term clinical results after the first treatment cycle (Cont et al. 2022). However, many aspects remain unclear concerning patient selection and treatment protocols.
Alzheimer’s disease (AD) is a very common cause of dementia in many countries all over the world and a common cause of death in elderly humans. No effective long-term treatment has been found yet.
Alzheimer”s disease (AD) is considered to be a progressive irreversible illness. So far an effective treatment of symptoms in Alzheimer”s disease has not yet been found. One of the symptoms often found in AD patients is the significant reduction of executive functions. Furthermore” affective fluctuations and depressive moods occur regularly. Transcranial pulse stimulation (TPS) induced by shock waves which were individually navigated according to current MRI-scans induced an amelioration of executive functions and reductions of depressive symptoms in patients with AD.
Alzheimer’s disease (AD) is a very common cause of dementia in many countries all over the world and a common cause of death in elderly humans. No effective long-term treatment has been found yet. TPS (Transcranial Pulse Stimulation), which can be individually tracked by MRT-scans, offers new perspectives to ameliorate deficits caused by AD. Pilot studies show beneficial effects on learning and memory of TPS. There are also reports of restorative structural changes in the thickness of the cerebral cortex due to the stimulation.
The Dementia syndrome is understood as being a disturbance of various cognitive functions, e.g. memory and orientation, over and above the average of those commonly experienced in old age. There are often pronounced deficits in social and employment everyday behaviour [1]. Primary and secondary dementia categories are recognized clinically: primary - the responsible alterations are to be found in the brain. Secondary - another illness of an organ apart from the brain is responsible [2]. Dementia is one of the most common psychiatric diseases in old age and dementia is very often first recognized at a late stage [1, 2]
Transcranial Pulse Stimulation (TPS) is a new non-invasive neuromodulation therapy that uses shockwaves for the treatment of Alzheimer´s Disease (AD). Recently, our group published short term clinical results after the first treatment cycle of 2 weeks (Cont et al., 2022). We found a significant improvement in the Alzheimer Disease Assessment Scale (ADAS) and in affective scores. Yet, no long-term results have been reported. Here we show first results after one stimulation cycle, 3 months, 6 months and up to 12 months.
Transcranial pulse stimulation (TPS) is a recent development in non-invasive brain stimulations (NIBS) that has been proven to be effective in terms of significantly improving Alzheimer patients’ cognition, memory, and execution functions. Nonetheless, there is, currently, no trial evaluating the efficacy of TPS on adults with major depression disorder (MDD) nationwide. In this single-blinded, randomized controlled trial, a 2-week TPS treatment comprising six 30 min TPS sessions were administered to participants. Participants were randomized into either the TPS group or the Waitlist Control (WC) group, stratified by gender and age according to a 1:1 ratio.
We participated in INS-IM 2022, a Neuromodulation conference at the Grand Hyatt Mumbai from November 11 to 13, 2022 in association with STORZ MEDICAL AG.
The Czech capital of Prague hosted the 24th edition of the ISMST World Congress (International Society for Medical Shockwave Treatment). Leading scientists and physicians from around the world presented the latest in research and practice in first-class lectures and workshops on all aspects of shock wave therapy.
Transcranial Pulse Stimulation (TPS) is a new non-invasive neuromodulation therapy that uses shockwaves for the treatment of Alzheimer ´ s Disease (AD). In humans, there is first evidence for beneficial clinical effects after a series of six TPS sessions. Long-term results and controlled trials are not yet reported. Experience from other centers is lacking. We report on first short-term and long-term clinical experience from a center in Germany with additional EEG recordings.
Ultrasound-based brain stimulation techniques may become a powerful new technique to modulate the human brain in a focal and targeted manner. However, for clinical brain stimulation no certified systems exist and the current techniques have to be further developed. Here, a clinical sonication technique is introduced, based on single ultrashort ultrasound pulses (transcranial pulse stimulation, TPS) which markedly differs from existing focused ultrasound techniques.In addition, a first clinical study using ultrasound brain stimulation and first observations of long term effects are presented. Comprehensive feasibility, safety, and efficacy data are provided.
Alzheimer’s disease (AD) is a very common cause of dementia in many countries all over the world and a common cause of death in elderly humans. No effective long-term treatment has been found yet. TPS (Transcranial Pulse Stimulation), which can be individually tracked by MRT-scans, offers new perspectives to ameliorate deficits caused by AD. Pilot studies show beneficial effects on learning and memory of TPS. There are also reports of restorative structural changes in the thickness of the cerebral cortex due to the stimulation.
Alzheimer's patients now also have access to Transcranial Pulse Stimulation (TPS) in Munich – one of the leading medical cities in Germany. In July 2021, a NEUROLITH system was installed in the private practice Schleicher & Brückl. It is the first NEUROLITH in the capital of Bavaria, the largest German state.
Transcranial Pulse Stimulation (TPS®) with the NEUROLITH® system for the treatment of Alzheimer's patients is increasingly gaining momentum: In early June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria and Turkey. In Germany, the Alexius/Josef Hospital in Neuss, with over 30 000 patients per year, opened a TPS® treatment centre under the direction of Prof. Dr Dr Dipl.-Psych. Ulrich Sprick (head physician of the outpatient services and day clinics). The respected specialist in psychiatry and psychotherapy is a lecturer at the Heinrich Heine University Düsseldorf and will work closely with STORZ MEDICAL in the future to further develop TPS®.
In early May 2021, two more NEUROLITH systems were installed in Germany. Both the renowned Klinikum Wahrendorff in Sehnde near Hanover and the private practice of Prof. Dr Musa Citak in Hamburg are expanding their range of therapies with Transcranial Pulse Stimulation (TPS).
There are various forms of brain stimulation, that are used in neurodegenerative disease. In this webinar neurologist Dr Lars Wojtecki talks about scientific background and clinical data of Transcranial Pulse Stimulation as well as practical experience with handling and clinical effects. Which patient to choose? How does TPS compare to TMS?
Transcranial Pulse Stimulation (TPS®) for the treatment of Alzheimer's patients is now also available for patients in Switzerland. In early February 2021, the first NEUROLITH® system was successfully installed in the Praxis Alexander Russ in Zurich.
Transcranial Pulse Stimulation (TPS®) for the treatment of Alzheimer's patients is now also available for patients in Switzerland. In early February 2021, the first NEUROLITH® system was successfully installed in the Praxis Alexander Russ in Zurich.
Watch the session »State of the Art of New Brain Stimulation Techniques« with Prof. Roland Beisteiner who presented on Transcranial Pulse Stimulation in patients with Alzheimer‘s disease on 12 November 2020.
We participated in INS-IM 2022, a Neuromodulation conference at the Grand Hyatt Mumbai from November 11 to 13, 2022 in association with STORZ MEDICAL AG.
The Czech capital of Prague hosted the 24th edition of the ISMST World Congress (International Society for Medical Shockwave Treatment). Leading scientists and physicians from around the world presented the latest in research and practice in first-class lectures and workshops on all aspects of shock wave therapy.
Transcranial Pulse Stimulation (TPS®) with the NEUROLITH® system for the treatment of Alzheimer's patients is increasingly gaining momentum: In early June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria and Turkey. In Germany, the Alexius/Josef Hospital in Neuss, with over 30 000 patients per year, opened a TPS® treatment centre under the direction of Prof. Dr Dr Dipl.-Psych. Ulrich Sprick (head physician of the outpatient services and day clinics). The respected specialist in psychiatry and psychotherapy is a lecturer at the Heinrich Heine University Düsseldorf and will work closely with STORZ MEDICAL in the future to further develop TPS®.
There are various forms of brain stimulation, that are used in neurodegenerative disease. In this webinar neurologist Dr Lars Wojtecki talks about scientific background and clinical data of Transcranial Pulse Stimulation as well as practical experience with handling and clinical effects. Which patient to choose? How does TPS compare to TMS?
Prof. Dr Roland Beisteiner from Medical University Vienna delves into the latest science on Transcranial Pulse Stimulation (TPS) with NEUROLITH® system, the research behind it, his work and the success to date. This new technique allows unprecedented focal neuronal tissue stimulation reaching depths of as much as 8 cm in the brain and reflects an unparalleled advancement in the field of transcranial stimulation.
Transcranial Pulse Stimulation (TPS) uses shockwaves for the treatment of Alzheimer´s patients. Recently, our group published short-term clinical results after the first treatment cycle (Cont et al. 2022). However, many aspects remain unclear concerning patient selection and treatment protocols.
Alzheimer’s disease (AD) is a very common cause of dementia in many countries all over the world and a common cause of death in elderly humans. No effective long-term treatment has been found yet.
Alzheimer”s disease (AD) is considered to be a progressive irreversible illness. So far an effective treatment of symptoms in Alzheimer”s disease has not yet been found. One of the symptoms often found in AD patients is the significant reduction of executive functions. Furthermore” affective fluctuations and depressive moods occur regularly. Transcranial pulse stimulation (TPS) induced by shock waves which were individually navigated according to current MRI-scans induced an amelioration of executive functions and reductions of depressive symptoms in patients with AD.
Alzheimer’s disease (AD) is a very common cause of dementia in many countries all over the world and a common cause of death in elderly humans. No effective long-term treatment has been found yet. TPS (Transcranial Pulse Stimulation), which can be individually tracked by MRT-scans, offers new perspectives to ameliorate deficits caused by AD. Pilot studies show beneficial effects on learning and memory of TPS. There are also reports of restorative structural changes in the thickness of the cerebral cortex due to the stimulation.
The Dementia syndrome is understood as being a disturbance of various cognitive functions, e.g. memory and orientation, over and above the average of those commonly experienced in old age. There are often pronounced deficits in social and employment everyday behaviour [1]. Primary and secondary dementia categories are recognized clinically: primary - the responsible alterations are to be found in the brain. Secondary - another illness of an organ apart from the brain is responsible [2]. Dementia is one of the most common psychiatric diseases in old age and dementia is very often first recognized at a late stage [1, 2]
We provide solutions for healthcare and research. We distribute medical equipment, provide scientific expertise and support to researcher
© 2020 Aerobe. All Rights Reserved Terms & Conditions | Privacy Policy